A Case of Longitudinal Extensive Transversal Myelitis in Patient With Neuromyelitis Optica Spectrum Disorder and Systemic Lupus Erythematosus Authors: Nikolina Pravdic, Marijana Goluza, Natasa Pejanovic Skobic, Davor Batinic, Jelena Zovko, Tanja Zovko, Anita Ivankovic, Inge Klupka Saric Published: 2026 ABSTRACT ABSTRACTNeuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune, demyelinating disorder of the central nervous system. Clinical manifestations include optic neuritis, longitudinally extensive transverse myelitis (LETM) involving three or more vertebral segments, and, in most cases, seropositivity for anti‐aquaporin‐4 antibodies (AQP4‐IgG). Although longitudinally extensive transverse myelitis (LETM) is a hallmark feature of NMOSD, it is not pathognomonic and may occur in a variety of infectious, metabolic, neoplastic, and autoimmune conditions, including systemic lupus erythematosus (SLE). Here we report the case of a female patient who presented with severe tetraparesis, secondary to transverse myelitis. Serological evaluation revealed positivity for anti‐AQP4 antibodies, anti‐dsDNA antibodies, and ENA antibodies, leading to the simultaneous diagnosis of NMOSD and SLE. Nevertheless, it remained uncertain whether the transverse myelitis represented a manifestation of NMOSD or neurological involvement of SLE.Keywords: anti‐aquaporin‐4 antibody (anti‐AQP4), neuromyelitis optica spectrum disorder (NMOSD), systemic lupus erythematosus, transverse myelitis Introduction Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune, demyelinating disease of the central nervous system. Clinical manifestations include optic neuritis, transverse myelitis involving three or more vertebral segments, and in most of the cases seropositivity for anti‐aquaporin‐4 antibodies (anti‐AQP4‐IgG) [1, 2, 3, 4, 5, 6, 7, 8]. Other recognized clinical manifestations of NMOSD include area postrema syndrome (intractable nausea, vomiting, and hiccups), acute brainstem syndrome, reversible posterior leukoencephalopathy syndrome, narcolepsy, and neuroendocrine dysfunction [3]. Spinal cord damage leads to symmetrical paraparesis or tetraparesis, urinary incontinence, sensory impairment, radicular pain, and a positive Lhermitte sign [7]. Previous studies have reported that NMOSD symptoms can sometimes be preceded by flu‐like symptoms [1]. Systemic lupus erythematosus (SLE) is a chronic systemic disease, sometimes with Central Nervous System (CNS) involvement, characterized by auto‐reactivity of the immune system, leading to auto‐antibody production and immune‐complex deposition within tissues. Myelitis in SLE can present as acute transverse myelitis, affecting one to two spinal segments, but its presentation as longitudinally extensive transverse myelitis (LETM) is uncommon [9]. Myelitis in SLE is usually a sign of worsening SLE and occurs 1–2 years after the onset of SLE, often accompanied by cerebral involvement. In NMOSD myelitis occurs several years later, and brain involvement is rare [7]. Before establishing the diagnosis of NMOSD, it is necessary to exclude other possible diseases as potential causes of paraparesis such as multiple sclerosis, Guillain Barre syndrome, and Myelin Oligodendrocyte Glycoprotein Antibody‐Associated Disease (MOGAD) [6]. The presence of serum anti‐aquaporin‐4 antibodies in the serum is a very specific test that can distinguish NMOSD from other diseases that come as part of differential diagnosis. Myasthenia gravis, thyroid diseases, ankylosing spondylitis, pernicious anemia, ulcerative colitis, Sjörgen's syndrome, and thrombotic thrombocytopenic purpura are diseases that have been reported in association with NMOSD. NMOSD is rarely described in occurrence with SLE [7]. Several reports have described cases in which neuromyelitis optica spectrum disorder (NMOSD) developed following a previously established autoimmune disease [10]. The mechanisms by which peripheral autoimmune diseases predispose to NMOSD remain unclear. However, it has been shown that systemic immune activation characterized by B‐ and T‐cell hyperactivity and increased cytokine production may facilitate the activation of AQP4‐reactive immune cells and the generation of pathogenic AQP4‐IgG antibodies, ultimately resulting in astrocytic damage and NMOSD development [10]. Nevertheless, the coexistence of NMOSD and SLE in a patient presenting with LETM poses significant diagnostic and therapeutic challenges, as there are currently no evidence‐based standardized treatment protocols for such cases [9, 11]. Case Presentation Presenting Complaints and Disease History A 51‐year‐old female patient, with well controlled hypothyroidism, presented to the hospital with acute symptoms that had begun 6 days earlier, consisting of epigastric pain radiating bilaterally to the back. On the following day, the patient developed urinary retention, tingling in both legs, and subsequent weakness in the legs (below the intermammillary line), along with mild weakness in the arms. In the 10 days prior, she had experienced a cold, with predominantly upper respiratory tract symptoms. Due to her febrile condition (up to 38°C), an infectious disease specialist was consulted. Because a viral CNS infection was suspected, empirical antiviral therapy was initiated. Subsequently, the patient was referred to the Department of Neurology of the University Clinical Hospital Mostar for further diagnostic workup and treatment. On neurological examination at admission, the patient exhibited severe paraparesis and mild weakness of both hands, with a positive Lhermitte's sign. Deep tendon reflexes in the lower extremities were symmetrically enhanced, and bilateral Babinski sign was positive. A sensory level was noted at Th6. Due to urinary retention, a urinary catheter was placed. Diagnostic Workup Diagnostic workup performed upon admission indicated hypothyroidism and hyperlipidemia (Table 1). Other laboratory parameters (glucose, urea, minerals, AST, ALT, total bilirubin, CK, CKMB, LDH, TSH, FT4, triglycerides, LDL cholesterol, ACE, folic acid, vitamin B12, b2 microglobulin, C3, C4, IgG, IgM, RF, C‐ANCA, P‐ANCA, U1‐SnRNP At, At against ribonucleic protein 70, Sm At, SS‐B/La At, At against centromeric protein B, Scl‐70 At, histidine‐t RNA synthetase At, At at b2‐glycoprotein 1‐IgG and IgM, At to cardiolipin IgG and IgM) were within the reference range. Blood cultures, tumor markers, and screening for blood‐borne infections were all unremarkable. TABLE 1Blood test results.TestPatient s resultsNormal referenceHemoglobin110119–157 g/LRed blood cells3.743.86–5.08 × 1012/LSedimentation582–13 mm/hHematocrit0.3510.356–0.47 L/LMCV81.383–97.2 fLMCH25.527.4–33.9 pgMCHC413.0320–345 g/LWhite blood cells12.33.4–9.7 × 109/LFibrinogen4.7Na+ 136137–146 mmol/LK+ 3.83.9–5.1 mmol/LHDL0.7> 1.2 mmol/LLDH101< 3 mmol/LFT33.624.26–8.1 pmol/LAntiTPO1836.280–5.6 IU/mLAntiTG3321.010–4.2 IU/mLCreatinine4649–90 umol/L25‐OH‐vitamin D27.275–100 nmol/L Blood test results. Cerebrospinal fluid analysis excluded a central nervous system infection (Table 2). Brain magnetic resonance imaging (MRI) revealed a linear hyperintense lesion measuring approximately 5 mm in the region of the right trigone of the lateral ventricle, without diffusion restriction, and was nonspecific. The lesion was considered nonspecific, most likely of vascular origin, although a demyelinating etiology could not be excluded. Additionally, a 4 mm hypointense lesion with subtle peripheral contrast enhancement was identified in the right frontal lobe, consistent with a cavernoma (Figure 1). MRI of the cervical and thoracic spinal cord demonstrated extensive intramedullary T2 hyperintensity. The cervical spinal cord was enlarged from C3 to C7, with patchy and nodular contrast enhancement. These findings were suggestive of an inflammatory myelopathy with NMOSD considered in the differential diagnosis (Figure 2). TABLE 2Cerebrospinal fluid analysis.ColorClear, colorlessChloride125Lactate2.20Pandy+Protein (g/L)0.9Cells count, n (%)21Limphocytes16 (76%)Monocytes5 (24%) Cerebrospinal fluid analysis. MRI of the brain showing a linear hyperintense lesion, approx. 5 mm in diameter, on the right side of the trigone of the lateral brain chamber, possible vascular or demyelinating etiology. An MRI of the cervical and thoracic spinal cord indicating presence of LETM. An additional comprehensive diagnostic workup was performed in accordance to the protocol for demyelinating diseases, chest radiography, abdominal ultrasound, and ophthalmologic examination. Serum samples were sent for analysis of paraneoplastic, anti‐MOG, and anti‐AQP4 antibodies. The detected anti‐AQP4 antibodies supported a diagnosis of NMOSD (Table 3). TABLE 3Serology test results.ENAPositiveAnti Ds‐DNAPositiveSS‐A/Ro atPositiveAnti‐MOGNegativeAnti Aquaporine 4Positive Serology test results. Therapeutic Intervention The patient was treated with pulse corticosteroid therapy, receiving high‐dose intravenous methylprednisolone 1 g/d for 5 days followed by a tapering course of oral corticosteroids. Because of the positive immunological findings (anti ds‐DNA and ENA antibodies), an immunologist was consulted, and noted a history of arthritis, photosensitivity, and alopecia (Table 3). After the diagnostic criteria were fulfilled, a diagnosis of SLE was established, and appropriate therapy was initiated, consisting of six pulses of cyclophosphamide (500 mg per dose) at 14‐day intervals. During the entire hospitalization, intensive physical rehabilitation was carried out. At discharge, neurological examination showed significant improvement, with persistent paraparesis but regained walking ability and slight improvement in urinary control. Conclusion and Results At each follow‐up visit, the patient showed slight improvement in neurological findings and regained significant functional recovery, with no relapses reported to date. This case contributes to the growing body of evidence suggesting that NMOSD and SLE may coexist as overlapping autoimmune disorders rather than entirely independent entities in selected patients. Although the exact pathogenic relationship remains incompletely understood, their coexistence creates substantial diagnostic and therapeutic challenges. Unlike most reported cases in which SLE or NMOSD had been diagnosed before the onset of myelitis, our patient presented with LETM as the initial manifestation that simultaneously led to the diagnosis of both disorders, further complicating etiological attribution and therapeutic protocol. Discussion NMOSD and systemic lupus erythematosus (SLE) are distinct and independent clinical entities [1]. Although longitudinally extensive transverse myelitis (LETM) represents an important diagnostic feature of NMOSD, it lacks specificity and should not be considered pathognomonic [12]. LETM may also occur in a wide range of other conditions, including infectious, metabolic, neoplastic, and autoimmune diseases. Although recorded in the literature, lupus‐induced acute transverse myelitis remains a rare and unusual complication of lupus, especially as an initial presentation, since neurological involvement in SLE most commonly presents as seizures, cerebrovascular events, psychosis, or cognitive impairment [8, 13]. In this case, serological analysis revealed the presence of anti‐AQP4, indicative of neuromyelitis optica spectrum disorder (NMOSD). Together with MRI findings of LETM and clinical presentation of tetraparesis our patient satisfied diagnostic criteria from 2015 required for the diagnosis of NMOSD [14]. However, additional serological evaluation revealed the simultaneous presence of lupus‐specific autoantibodies (anti‐dsDNA, ENA antibody) that, with additional clinical features, including a history of arthritis, photosensitivity, and alopecia, further supported the concurrent presence of SLE. The occurrence of longitudinally extensive transverse myelitis (LETM) in our patient within this immunological context constitutes a significant diagnostic challenge, as both SLE and NMOSD are capable of producing myelitis, so the chronological sequence of disease onset and the precise etiological contribution of each disorder to the myelitis remain indeterminate. While some reports suggest that NMOSD may arise secondary to a pre‐existing autoimmune condition, others describe cases in which NMOSD precedes other autoimmune pathology, including SLE. Pathogenic anti‐aquaporin‐4 (AQP4) antibodies in NMOSD are responsible for the neuroinflammation and secondary demyelinating lesions, and they can be the mediators of the neuroinflammatory process in SLE patients. It is considered distinct from the immunopathogenesis that includes vascular and immune‐complex‐mediated mechanisms associated with myelitis seen in traditional neuropsychiatric SLE [10, 12]. While in most previously described cases, NMO was diagnosed in patients with previously clearly defined SLE, the important clinical message of this case is the diagnostic uncertainty that arises when longitudinally extensive transverse myelitis occurs in a patient fulfilling criteria for both disorders simultaneously. Furthermore, this case highlights an important therapeutic dilemma. While treatment strategies for NMOSD and lupus myelitis overlap, they are not identical, and evidence‐based recommendations for patients fulfilling criteria for both diseases remain limited. Treatment decisions should focus on rapid suppression of inflammation and prevention of permanent spinal cord injury [15]. In accordance with standard treatment guidelines for acute attacks transverse myelitis, our patient received high‐dose intravenous corticosteroid therapy (methylprednisolone 1 g/day during five days) with gradual tapering and discontinuation. As was emphasized by several authors, the importance of early initiation of high‐dose corticosteroids in combination with cyclophosphamide in patients with transverse myelitis associated with SLE, cyclophosphamide therapy was initiated in our patient in an effort to optimize neurological recovery [15]. Imunotherapy with rituximab, anti CD 19 antibodies like inebilizumab, and interleukin 6 receptor antagonists like satralizumab are recommended for treatment of NMOSD, although multiple observational studies suggest that agents such as azathioprine, methotrexate, and mycophenolate mofetil can be efficaciously employed to treat NMOSD, leading tofavourable clinical outcomes [16]. There are no specific recommendations for the treatment of overlapping cases of these two diseases, and the management of TM is mostly limited to clinical cases and series. Recommendations for NMOSD treatment could be a reference for SLE‐TM patients who meet the NMOSD criteria [12]. According to literature, in cases where longitudinally extensive transverse myelitis with AQP‐4IgG antibodies coexists with SLE, transverse myelitis should be treated as part of NMOSD [9, 10]. Patients with concomitant NMOSD and SLE often exhibit suboptimal therapeutic responses, a pattern observed in the present case, although partial recovery of neurologic deficit occurred. Our patient demonstrated several factors previously associated with poor prognosis, including high anti‐AQP4 antibody level, early onset of motor deficits, and the presence of extensive spinal lesion [12]. Distinguishing between NMOSD‐associated myelitis and SLE‐related myelitis remains clinically challenging. Our and previous findings showed the complex interaction between autoimmune diseases and highlight the importance of using serological, imaging, and clinical data together when evaluating patients with overlapping autoimmune conditions. Considering that recommendations for the treatment of NMOSD may differ from those of co‐existing autoimmune conditions, careful planning of treatment is required. Further research is needed to establish standardized diagnostic and treatment guidelines in this challenging group of patients. Author Contributions Nikolina Pravdic: conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, project administration, resources, software, supervision, visualization, writing – original draft, writing – review and editing. Marijana Goluza: conceptualization, data curation, formal analysis, investigation, resources, writing – original draft. Jelena Zovko: data curation, investigation, software, supervision, validation. Davor Batinic: funding acquisition, investigation, methodology, supervision. Natasa Pejanovic Skobic: conceptualization, formal analysis, project administration, writing – original draft. Tanja Zovko: methodology, software, supervision, visualization. Anita Ivankovic: conceptualization, data curation, funding acquisition, project administration, resources. Inge Klupka Saric: investigation, resources, supervision, visualization. Funding The authors have nothing to report. Consent The signed informed consent was obtained from the patient for the publication of the case report. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments The authors have nothing to report. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.